Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Liraglutid, ATC A10BJ02 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a (8) SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, containing the active substance Liraglutid, ATC A10BJ02, DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until new pharmaceutical discount contracts come into force. A discount contract under the approval model for the aforementioned active substance comes into force for the first time on 01.03.2026 and ends on 29.02.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.